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Abstract
Tobacco smoke is an established carcinogen, but the association between tobacco smoking and 
cancer risk in BRCA mutation carriers is not clear. The aim of this study was to evaluate 
prospectively the association between tobacco smoking and cancer incidence in a cohort of 
BRCA1 and BRCA2 mutation carriers. The study population consisted of unaffected BRCA 
mutation carriers. Information on lifestyle including smoking histories, reproductive factors, and 
past medical histories was obtained through questionnaires. Incident cancers were updated 
biennially via follow-up questionnaires. Hazard ratios (HRs) and 95% confidence intervals (CIs) 
were estimated using time-dependent Cox regression models. There were 700 incident cancers 
diagnosed over 26,711 person-years of follow-up. The most frequent cancers seen in BRCA 
mutation carriers were breast (n = 428; 61%) and ovarian (n = 109; 15%) cancer. Compared to 
non-smokers, (ever) smoking was associated with a modest increased risk of all cancers combined 
(HR = 1.17; 95%CI 1.01–1.37). Women in the highest group of total pack-years (4.3–9.8) had an 
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increased risk of developing any cancer (HR = 1.27; 95%CI 1.04–1.56), breast cancer (HR=1.33, 
95%CI 1.02–1.75), and ovarian cancer (HR = 1.68; 95%CI 1.06–2.67) compared to never 
smokers. The associations between tobacco smoking and cancer did not differ by BRCA mutation 
type or by age at diagnosis. This prospective study suggests that tobacco smoking is associated 
with a modest increase in the risks of breast and ovarian cancer among women with BRCA1 or 
BRCA2 mutation.
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Introduction
Cigarette smoking has been categorized as a group 1 carcinogen by the International Agency 
for Research, in particular for cancers of the lung, bladder, liver, and colon.1, 2 Although 
smoking and the risk of developing breast or ovarian cancer is not conclusive, recent meta-
analyses of the prospective studies suggest a 13% increased risk of breast cancer (relative 
risk [RR] = 1.13; 95% confidence intervals [CI] 1.09–1.17) and no increase in the risk of 
ovarian cancer (RR = 1.06; 95%CI 0.99–1.12) for current smokers compared to never 
smokers.3, 4 These risk estimates are derived from studies conducted in the general 
population.
Women with inherited mutations in BRCA1 or BRCA2 face high lifetime risks of 
developing breast and ovarian and other cancers.5, 6 The incomplete penetrance of a BRCA 
mutation implies that exogenous factors may modify cancer risk.7, 8 The identification of 
modifiable exposures is critical for this high-risk population, given that effective prevention 
strategies are currently limited to prophylactic surgery. Cigarette smoking is of interest in 
this respect because it is modifiable. Furthermore, because of the important role of the 
BRCA proteins in the repair of double stranded DNA breaks as well as damage due to 
oxidative stress, mutation carriers may be more susceptible to the relevant carcinogens.9
It is not clear if cigarette smoking is a risk factor for cancer in this high-risk population. A 
number of earlier reports, including two from our group, have yielded inconclusive results 
and have been limited by small sample sizes and retrospective study designs, which are 
vulnerable to selection bias and information bias.10–16 We undertook a prospective 
evaluation of cigarette smoking and overall cancer incidence, as well as breast and ovarian 
cancer incidence, in a large cohort of BRCA1 and BRCA2 mutation carriers.
Materials and Methods
Study population
The study population was selected from a multicenter longitudinal cohort of BRCA1 and 
BRCA2 mutation carriers from 80 participating centers in 17 countries including North 
America, Europe, Asia, the Caribbean, and Latin America. These women sought genetic 
testing for a BRCA1 or BRCA2 mutation because of a personal or family history of breast 
and/or ovarian cancer and genetic counselling was conducted for all study subjects (with the 
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exception of some from the University of Utah and University of California Irvine). 
Mutation detection was conducted using a range of techniques, but all nucleotide sequences 
were confirmed by direct sequencing of DNA. Informed consent was obtained from all 
participants and the study protocol was approved by the institutional ethics review board of 
each host institution.
Data collection and ascertainment of incident cancers
All study subjects completed a baseline questionnaire at the individual center at the time of a 
clinic appointment or at their home at a later date. The questionnaire requested information 
on family and personal history of cancer, reproductive and medical histories, including 
preventive oophorectomy and mastectomy. Follow-up questionnaires were completed every 
two years thereafter and administered by mail or completed over the phone by a genetic 
counsellor or research assistant. At each follow-up, participants provided updates on 
exposures, preventive surgery and cancer incidence. The questionnaire also collected 
detailed information on past and current regular cigarette smoking history including: age 
first started to smoke, age last smoked, and the average number of cigarette packs smoked 
per week. Incident breast cancers (invasive breast cancer only) and ovarian cancers were 
identified by self-report, and 85% of breast cancer cases and 63% of ovarian cancer cases 
were confirmed by review of pathology reports. In the contributing Korean institutions, 
incident cancer cases were ascertained by the national cancer registry.
Study Subjects Available for Analysis
There were 15,731 women with a BRCA1 or BRCA2 mutation who were potentially 
eligible for inclusion in the current study. Of the 15,731 women, we excluded subjects who 
had a previous diagnosis of any cancer (n = 8,541), had no information on smoking history 
(n = 542), or had no follow-up information (n = 2,372). After these exclusions, a total of 
4,276 subjects qualified for inclusion in the analysis. For the analysis of tobacco smoking 
with breast and ovarian cancer, we additionally excluded the subjects who had a 
prophylactic mastectomy (n = 209) and oophorectomy (n = 854) at baseline, respectively, 
and we excluded those who had missing information on prophylactic surgery during the 
follow-up period (n = 147). There was a total of 3,920 subjects in the analysis for breast 
cancer and 3,275 subjects for ovarian cancer.
Statistical analysis
Time dependent Cox regression analysis was used to estimate the hazard ratios (HRs) and 
95% confidence intervals (CIs) of all cancer as well as breast and ovarian cancer, with 
smoking. All the smoking exposures, as well as the covariates, included in the analyses were 
treated as time-dependent variables and updated to reflect the any changes following 
completion of the baseline questionnaire or at any point in the follow-up. In the analysis of 
smoking and all cancers (as well as breast cancer specific incidence), the continuous 
variables of exposures were categorized into quartiles groups based on the distribution in the 
entire cohort. For the analysis of ovarian cancer, continuous variables of exposures were 
categorized into 3 groups (never smoker, and dichotomization of exposed group by median) 
based on the distribution in the entire cohort.
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We created the following smoking variables: 1) smoking history (ever, never), 2) current 
smoking history (non-smoker, past smoker, current smoker), 3) age first started to smoke 
(never, ≥ 20 years, 18–19 years, ≤ 17 years for overall and breast cancer analysis; never, > 
19 years, ≤ 19 years for ovarian cancer analysis), 4) average packs smoked per week (never, 
≤ 2 packs, 2 < packs ≤ 5, >5 packs for overall and breast cancer analysis; never, ≤ 3 packs, > 
3 packs for ovarian cancer analysis), 5) smoking duration (never, ≤ 8 years, 8 < years ≤ 18, 
>18 years for overall and breast cancer analysis; never, ≤ 10 years, > 10 years for ovarian 
cancer analysis), and 6) total pack-years (never, ≤ 2.3 pack-years, 2.3 < pack-years ≤ 9.8, > 
9.8 pack-years for overall and breast cancer analysis; never, ≤ 4.3 pack-years, > 4.3 pack-
years for ovarian cancer analysis). Total pack-years smoked was estimated by the following 
equation: (cigarette packs smoked per day) × (total years smoked). 7) duration 
of smoking before first birth among parous women (never smoker, smoking initiation after 
first birth, ≤ 5 years, and > 5 years). For the analysis of overall cancer incidence, participants 
were followed from the date of baseline questionnaire until either the: 1) date of completion 
of the last follow-up questionnaire, 2) date of cancer diagnosis, or 3) date of death. For the 
analysis of breast cancer incidence, participants were followed from the date of baseline 
questionnaire until either the: 1) date of completion of the last follow-up questionnaire, 2) 
date of breast cancer or ovarian cancer diagnosis, 3) date of prophylactic mastectomy, or 4) 
date of death and similarly for ovarian cancer incidence except for censoring at date of 
prophylactic oophorectomy instead of date of prophylactic mastectomy.
The multivariate model was adjusted for age (continuous), country of residence (Canada and 
United States/Europe/others [including Asia and Latin America]), BRCA mutation type 
(BRCA1 or BRCA2), pregnancy history (ever/never), oral contraceptive use (ever/never), 
regular alcohol consumption (ever/never) and obesity (normal, less than 25 kg/m2/
overweight, 25–29.9 kg/m2/obese, 30 kg/m2 or more). We also performed analyses stratified 
by BRCA1 and BRCA2 mutation, age at breast cancer diagnosis (<50 vs. ≥50 years), and 
ER status of breast cancer cases.
The P for trend was estimated by treating the numerical values of the categorical variables as 
a score in time-dependent Cox regression model to assess dose-response relationships. All 
analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA) and a P value less 
than 0.05 was considered as statistical significance.
Results
A total of 4,276 women with a BRCA1 or BRCA2 mutation were included in the current 
prospective analysis. The age-adjusted baseline characteristics by smoking history are shown 
in Table 1. Women who smoked were, on average, older (40.4 years vs. 38.1 years), more 
likely to be BRCA1 mutation carriers (78% vs. 21%), to have been pregnant (43% vs. 31%), 
and to have breastfed for a longer duration (compared to women who never smoked (all 
comparisons P < 0.01). Smokers were more likely to have used oral contraceptives (42% vs. 
36%), to have a greater BMI (mean 24.7 vs. 24.0 kg/m2), to live in Europe (54% vs. 43%), 
to consume alcohol (45% vs. 28%) and to consume coffee regularly (46% vs. 24%) 
compared with never smokers (all comparisons P < 0.01).
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Average follow up time for smokers and nonsmokers was 6.5 and 6.1 years, respectively. 
Average age at diagnosis of any cancer for smokers and nonsmokers was 49.3 and 47.4 years 
old, respectively. During the entire follow-up period of 26,711 person-years, 700 incident 
cancers were identified. These are summarized by BRCA mutation type in Supplemental 
table 1. Among the 3,256 BRCA1 mutation carriers, there were 544 incident cancers and 
among the 987 BRCA2 mutation carriers, there were 153 incident cancers. The most 
commonly diagnosed cancers in BRCA mutation carriers were breast cancer (n=339; 10.4% 
in BRCA1 mutation carriers and n=87; 8.8% in BRCA2 mutation carriers) and ovarian 
cancer (n=103; 3.2% in BRCA1 mutation carriers and n=6; 0.6% in BRCA2 mutation 
carriers). Other commonly diagnosed cancers included ductal carcinoma in situ or lobular 
carcinoma in situ, as well as cancers of the skin, peritoneal and fallopian tube. With respect 
to smoking related cancers, there were nine pancreatic cancers, seven lung cancers and one 
bladder cancer diagnosed in the entire cohort.
The association between cigarette smoking and the risk of developing cancer at any site is 
shown in Table 2. Ever smokers had a 17% increased risk of developing any cancer 
compared to never smokers (HR=1.17; 95% CI 1.01–1.37). Current smokers had a 31% 
increased risk of developing cancer compared to never smokers (HR=1.31; 95% CI 1.07–
1.59; P trend = 0.01). Earlier age at first smoking was associated with a significant 
increasing risk of developing cancer compared to never smoking (P-trend = 0.03). Increasing 
duration of smoking was associated with a significant increasing risk of developing cancer 
compared to never smoking (P-trend < 0.01). Women in the highest category of total pack-
years of smoking (i.e., >9.8) had a 27% increased risk of cancer compared to women who 
never smoked (HR=1.27; 95% CI 1.04–1.56; P -trend = 0.02). Average packs of cigarette 
smoked per week (P-trend = 0.13) were not associated with the risk of any cancer.
Table 3 summarizes the results for the analysis of cigarette smoking and breast cancer risk. 
Ever smoking was not significantly associated with the risk of breast cancer (HR = 1.16; 
95%CI 0.96–1.41). Current smokers had a 28% increased risk of breast cancer compared to 
never smokers (HR=1.28; 95% CI 1.00–1.64; P -trend = 0.07). Women in the highest 
quartile of smoking duration had a 34% increased risk of developing breast cancer compared 
to women who never smoked (HR=1.34; 95% CI 1.04–1.73; P -trend = 0.02). Women in the 
highest quartile of total pack-years had a 33% increased risk of developing breast cancer 
compared to never smokers (HR=1.33; 95% CI 1.02–1.75; P-trend = 0.08). There was no 
significant association between age at smoking initiation (P-trend = 0.39), duration 
of smoking before the first birth among parous women (P-trend = 0.77) or average packs 
smoked per week (P-trend = 0.22) and the risk of developing breast cancer.
Past smokers had a 69% increased risk of developing ovarian cancer compared to never 
smokers (HR 1.69; 95% CI 1.06–2.71)(Table 4). Current smoking was not significantly 
associated with risk (HR = 1.25; 95%CI 0.73–2.12). Women who smoked for 10 or more 
years had a 63% increased risk of developing ovarian cancer compared to women who never 
smoked (HR=1.63; 95% CI 1.04–2.54). Total pack-years of more than 4.3 was associated 
with the increased risk of ovarian cancer compared with never smoking (HR=1.68; 95% CI 
1.06–2.67). There was a significant dose-response relationship between both smoking 
duration and total pack-years and the risk of developing ovarian cancer (P-trend = 0.03).
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The associations between tobacco smoking and overall cancer, as well as breast and ovarian 
cancer were similar in analyses stratified by BRCA mutation type (P heterogeneity > 0.05, 
Supplementary tables 2–4) and age at diagnosis (P heterogeneity > 0.05; data not shown).
Discussion
In this prospective evaluation of cigarette smoking and cancer risk among women with an 
inherited BRCA1 or BRCA2 mutation, we observed a borderline significant increased risk 
of developing any cancer, as well as breast and ovarian cancer specifically, with a history of 
smoking. Compared to never smokers, both increasing duration of smoking and pack-years 
of smoking were associated with a significant 1.3-fold increased risk of all cancers and of 
breast cancer, as well as a 1.6-fold increased risk of ovarian cancer. Although we found no 
significant associations between age at first use or average packs smoked per week, there 
was a consistent and significant dose-response relationship between lifetime dose of 
smoking (measured as total pack-years) and long-term exposure (measured as duration of 
smoking) with cancer risk. The results from this large prospective analyses implicate 
smoking as a likely carcinogen in this high-risk population, which we estimate confers a 
30% and 60% increased risk of developing BRCA-associated breast and ovarian cancer, 
respectively.
Among studies conducted in the general population, causal links between cigarette smoking 
and 17 different types of cancers of the lung, bladder, liver, colorectal cancer has previously 
confirmed.2 Although the number of smoking-related cancers in the current study was low, 
we observed a 1.3-fold increased risk of cancer overall with smoking history (including 
duration of smoking and total pack-years) which is in accordance with risk estimates from 
epidemiologic reports stemming from women in the general population. To our knowledge, 
there are no prior evaluations of smoking and total BRCA-cancer incidence.
Although the evidence on tobacco smoking for breast cancer is not sufficient to infer a 
causal relationship in general population, a recent meta-analysis of the prospective studies 
estimated a significant 13% increased risk of breast cancer with current smoking (summary 
RR = 1.13; 95% CI 1.09–1.17).3 The observed adverse effect of smoking was greater than 
this in our cohort of high-risk women, which current smoking was associated with 28% 
increased risk of breast cancer. Also we observed a 33%-34% increased risk of BRCA-
associated breast cancer with increasing duration and pack-years. A retrospective cohort 
study of smoking and cancer in BRCA mutation carriers, which included 990 women, 
reported a 2.1-fold increased risk of breast cancer among women with more than 20 pack-
years of smoking.15 Limitations of the latter analysis is that follow-up was initiated at birth 
and women were followed until a cancer diagnosis or the date of interview and prevalent 
cases were included.
Our current findings contrast with our earlier reports that similarly assessed the association 
between smoking and breast cancer among BRCA mutation carriers (a subset of which were 
also included in the current analysis).12, 13 In the first report by our group which included 
186 matched cases and controls, we reported a significant reduction in BRCA-breast cancer 
risk among women who smoked more than four pack-years (odds ratio [OR] = 0.46; 95% CI 
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0.27–0.80).14 In an updated analysis with a substantially larger number of BRCA mutation 
carriers (1,097 matched cases and controls), Ghadirian et al., found no association between 
smoking and the risk of breast cancer compared to never smoking (OR for ever smoking = 
1.05; 95% CI 0.88–1.25 and OR for > 20 pack-years = 0.81; 95% CI 0.57–1.15).12 Finally, 
in our most recent report with 2,538 matched pairs, ever smoking were not associated with 
the risk of breast cancer regardless of BRCA1 or BRCA2 mutation, although a past history 
of smoking was associated with a significantly increased risk of breast cancer among 
BRCA1 carriers but not BRCA2 mutation carriers.13
In a small retrospective cohort study of BRCA1 mutation carriers (176 cases and 140 non-
cases), ever smoking was associated with a decreased risk of breast cancer (HR = 0.63; 95% 
CI 0.47–0.87) and this inverse association was attenuated in the women with a 28 repeat 
allele for steroid receptor co-activator gene AIB1 (hazard ratio = 0.19; 95% CI 0.07–0.54).11 
A case-control study composed of BRCA mutation aged less than 50 years old with reported 
that smoking history and high pack-years of smoking were associated with an increased risk 
of breast cancer with an estimated average of 7% increase per pack-year of smoking in 
BRCA mutation carriers.10 These prior reports were retrospective analyses and limited by a 
relatively smaller number of BRCA mutation carriers. Furthermore, in the case-control 
studies published by our team, there was an average of eight years between the date of 
diagnosis to date of interview or genetic testing, and thus, the analyses were vulnerable to 
survival and recall bias.
A recent pooled analysis in the general population from 14 cohort studies found an 18% 
increased risk of developing breast cancer among women who smoked 10 or more years 
prior to their first pregnancy compared to women who never smoked (HR = 1.18; 95% CI 
1.12–1.24).17 Duration of smoking before the first birth among parous women was emerging 
risk factor for breast cancer in relation to the timing of smoking initiation.18, 19 Given the 
early age at breast cancer onset among BRCA mutation carriers (between ages 30 and 50), it 
is plausible that early exposures may significantly impact risk. Thus, we also evaluated the 
effect of smoking by age at first use, duration of smoking before first birth, and age at 
diagnosis; however, we found no evidence for an effect of this classification of smoking 
exposure on risk. Our study showed that heavy smoking with long time exposure was the 
important attributor in the development of breast cancer regardless of exposure timing, 
diagnosed age for breast cancer, and BRCA mutation type.
We observed a borderline significant 1.6-fold increased risk of ovarian cancer among women 
in the highest tertile of both smoking duration and total pack-years compared to never 
smokers. One other study has evaluated the relationship between smoking and ovarian 
cancer among BRCA mutation carriers.20 In this matched case-control study of Polish 
women with BRCA1 mutations (150 cases and 150 controls), smoking was not associated 
with ovarian cancer (OR = 1.3; 95% CI 0.8–2.3).20 Among women in the general population 
the relationship between smoking and ovarian cancer varies by histologic subtype; current 
smoking is associated with an increased risk of mucinous ovarian cancer compared to never 
smoking (RR=1.79; 95% CI 1.47–2.17), a decreased risk of endometrioid ovarian cancer 
(RR=0.81; 95% CI 0.70–0.94)4 but is not associated with the serous subtype (RR=0.99; 95% 
CI 0.91–1.08) or the clear-cell subtype (RR=0.80; 95% CI 0.63–1.01) in meta-analysis from 
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51 studies. Histologically, mucinous ovarian cancer are similar to cancers of the intestinal 
epithelium, which are also well-known smoking-related cancer.2 The findings from studies 
of women in the general population (who are likely not mutation carriers) contrasts with our 
current findings given that BRCA-ovarian cancers are predominantly of the serous or 
endometrioid subtypes.4, 21
Tobacco contains more than 7,000 chemical compounds including benzo[a]pyrene, 
hydrocarbons, tobacco-specific nitrosamines, benzene, formaldehyde, carbon monoxide 
cyanide, and polonium, the majority of which are well-established carcinogens and toxins.16 
These components of tobacco smoke have been shown to contribute to carcinogenesis via 
multiple pathways, including DNA binding and consequent induction of mutation, 
inflammation, oxidative stress, and epigenetic mechanisms.22 Given the important role of 
the BRCA proteins in the repair of double-stranded DNA breaks, this population of women 
may be more susceptible to damage caused which could be caused from oxygen species by 
smoking23 The underlying mechanisms to explain the carcinogenic effects of cigarette 
smoking for breast cancer include the detection of circulating metabolites such as polycyclic 
aromatic hydrocarbons, aromatic amines, and N-nitrosamines in breast tissue and p53 
mutation.24, 25 In contrast, anti-carcinogenic effects of smoking for breast cancer have also 
been suggested because of the anti-estrogenic effects of tobacco26, 27 Specifically, smoking 
has been shown to have inverse association with mammographic density which is a 
biomarker of breast cnacer.28, 29
Our study had several limitations including the ascertainment of incident cancers via 
questionnaire and our inability to confirm all reported cancers by medical record review. 
Although this may have resulted in misclassification of the outcome variables, self-report of 
cancer incidence has previously been shown to be valid and reliable, particularly for breast 
cancer.30–32 The sensitivity of self-reported cancer in women has been estimated between 
0.61 and 0.89, while the sensitivity for breast cancer (the major incident cancer in our 
population) is high (range 0.85–0.91).30–32 Loss to follow-up is inevitable in prospective 
studies and can result in selection bias attributed to differences in the distribution of the 
exposure variable among subjects with and without follow-up information.33 In our study 
population, we did not have follow-up information on 36 % (2,372 subjects of 6,648 
subjects) of the baseline participants, and thus, we could not ascertain the cancer incidence. 
Nevertheless, the proportion study subjects with follow-up information did not differ by 
smoking status in our population of BRCA mutation carriers (i.e., 66% in ex-smokers or 
current smokers) vs. 63% in never smokers. Also we could not find obvious association in 
the stratified analysis because of small sample size.
Despite these limitations, the current study had several strengths including the large sample 
of BRCA mutation carriers (n = 4,276) with a relatively long follow-up period (median = 5.4 
years and interquartile range = 3.1 to 8.8 years). The prospective nature of our study design 
allowed for data collection prior to disease incidence, minimizing both selection and 
information bias. We reduced the influence of measurement error by using biennial follow-
up questionnaires to update both exposures and covariates.
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In conclusion, findings from this large prospective analysis of smoking and BRCA-
associated cancers clearly implicates smoking as a risk factor, particularly for breast and 
ovarian cancer, the most common type of cancers diagnosed in this high-risk population. 
The adverse health effects of smoking should be discussed by clinicians and genetic 
counsellors managing women with BRCA-associated cancers. The impact of smoking on 
cancers incidence in male BRCA mutation carriers warrants further study.
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Novelty Impact Statement
Findings from this large prospective analysis of smoking and BRCA-associated cancers 
clearly implicates smoking as a risk factor, particularly for breast and ovarian cancer, the 
most common type of cancers diagnosed in this high-risk population. The adverse health 
effects of smoking should be discussed by clinicians and genetic counsellors managing 
women with BRCA-associated cancers. The impact of smoking on cancers incidence in 
male BRCA mutation carriers warrants further study.
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Table 1
Baseline characteristics of BRCA mutation carriers by smoking status
Variables Non-smoker (n=2,566) Smoker (n=1,710) P-value*
Age, years (mean ± SD) 38.1 ± 12.6 40.4 ± 11.6 < 0.01
BMI, kg/m2 (mean ± SD) 24.0 ± 4.8 24.7 ± 5.0 < 0.01
Country, n (%)
 US/Canada 1,248 (48.6) 747 (43.7)
 Europe 1,113 (43.4) 923 (54.0)
 The others 205 (8.0) 40 (2.3) < 0.01
BRCA mutation, n (%)
 BRCA1 mutation 1,918 (74.8) 1,338 (78.3)
 BRCA2 mutation 627 (24.4) 360 (21.1)
 BRCA1 and BRCA2 mutation or unknown 21 (0.8) 12 (0.7) < 0.01
Pregnancy history, n (%)
 Never 781 (30.5) 349 (20.5)
 Ever 1,782 (69.5) 1,357 (79.5) < 0.01
Breastfeeding duration, n (%)
 Never 1,033 (44.6) 624 (40.1)
 Less than 6 months 430 (18.6) 398 (25.6)
 More than 6 months 854 (36.9) 533 (34.3) < 0.01
Menarche age, n (%)
 ≤ 13 years 886 (35.6) 581 (34.7)
 14 years 713 (28.6) 467 (27.9)
 ≥15 years 892 (35.8) 627 (37.4) 0.75
Menopausal status, n (%)
 Premenopausal 1,841 (72.1) 1,114 (65.2)
 Postmenopausal 711 (27.9) 596 (34.8) 0.40
Oral contraceptive use, n (%)
 Never 1,027 (40.2) 576 (33.9)
 Ever 1,529 (59.8) 1,121 (66.1) < 0.01
HRT use, n (%)
 Never 2,192 (86.1) 1,398 (82.7)
 Ever 354 (13.9) 292 (17.3) 0.37
Tamoxifen use, n (%)
 Never 2,325 (97.8) 1,619 (98.0)
 Ever 51 (2.2) 33 (2.0) 0.21
Regular alcohol drinker, n (%)
 No 867 (34.3) 339 (20.2)
 Yes 1,661 (65.7) 1,340 (79.8) < 0.01
Regular coffee consumer, n (%)
 No 818 (34.2) 253 (15.6)
 Yes 1,574 (65.8) 1,365 (84.4) < 0.01
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Variables Non-smoker (n=2,566) Smoker (n=1,710) P-value*
Prophylactic mastectomy history, n (%)
 No 2,407 (95.1) 1,589 (94.9)
 Yes 123 (4.9) 86 (5.1) 0.95
Oophorectomy history, n (%)
 No 2,063 (81.2) 1,325 (77.9)
 Yes 477 (18.8) 377 (22.1) 0.75
*
adjusted for age using logistic regression
BMI, body mass index; HRT, hormone replacement therapy
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Table 2
Association between smoking and risk of all cancer incidence among BRCA mutation carriers
Person-years (Total 26,711) Incident cases (N = 700) Crude HR (95% CI) Adjusted HR* (95% CI)
Smoking history
 Never 15,335 359 Reference Reference
 Ever 11,377 341 1.28 (1.11–1.49) 1.17 (1.01–1.37)
Current smoking history
 Past smoker 6,243 184 1.27 (1.06–1.51) 1.09 (0.91–1.31)
 Current smoker 5,050 153 1.29 (1.07–1.56) 1.31 (1.07–1.59)
P for trend = < 0.01 0.01
Age at first smoking
 ≥ 20 years 3,767 115 1.31 (1.06–1.61) 1.08 (0.87–1.34)
 18–19 years 3,129 93 1.27 (1.01–1.60) 1.20 (0.95–1.51)
 ≤ 17 years 4,247 119 1.20 (0.98–1.48) 1.22 (0.99–1.51)
P for trend = < 0.01 0.03
Average packs smoked/week
 <2 packs 3,006 80 1.14 (0.90–1.46) 1.09 (0.85–1.39)
 2 ≤ packs < 5 3,757 101 1.15 (0.92–1.43) 1.10 (0.88–1.38)
 5 ≤ packs 3,685 115 1.34 (1.08–1.65) 1.17 (0.95–1.45)
P for trend = 0.01 0.13
Smoking duration
 ≤ 8 years 3,796 70 0.79 (0.61–1.02) 0.88 (0.68–1.14)
 8 < duration ≤ 18 3,400 93 1.17 (0.93–1.47) 1.18 (0.93–1.48)
 18 < duration 3,968 166 1.80 (1.50–2.17) 1.37 (1.13–1.66)
P for trend = < 0.01 < 0.01
Total pack-years
 ≤ 2.3 pack-years 3,424 71 0.89 (0.69–1.15) 0.96 (0.75–1.25)
 2.3< pack-years ≤ 9.8 3,342 91 1.16 (0.92–1.46) 1.12 (0.89–1.41)
 > 9.8 pack-years 3,534 131 1.59 (1.30–1.95) 1.27 (1.04–1.56)
P for trend = < 0.01 0.02
*
adjusted for age, country, BRCA mutation, pregnancy history, contraceptive drug use, alcohol drinking and obesity using time-dependent Cox 
regression model
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Table 3
Association between smoking and risk of breast cancer among BRCA mutation carriers
Person-years (Total 21,098) Incident cases (N = 420) Crude HR (95% CI) Adjusted HR* (95% CI)
Smoking history
 Never 11,990 217 Reference Reference
 Ever 9,108 203 1.22 (1.01–1.48) 1.16 (0.96–1.41)
Current smoking history
 Past smoker 4,835 104 1.16 (0.92–1.47) 1.04 (0.82–1.32)
 Current smoker 4,250 95 1.24 (0.98–1.58) 1.28 (1.00–1.64)
P for trend = 0.06 0.07
Age at first smoking
 ≥ 20 years 3,165 75 1.29 (0.99–1.67) 1.15 (0.88–1.51)
 18–19 years 2,584 52 1.10 (0.82–1.49) 1.08 (0.79–1.47)
 ≤ 17 years 3,223 65 1.11 (0.84–1.45) 1.12 (0.84–1.48)
P for trend = 0.34 0.39
Average packs smoked/week
 <2 packs 2,413 47 1.06 (0.77–1.45) 1.04 (0.76–1.43)
 2 ≤ packs < 5 3,086 59 1.05 (0.79–1.41) 1.04 (0.77–1.39)
 5 ≤ packs 2,783 67 1.32 (1.01–1.74) 1.22 (0.92–1.61)
P for trend = 0.08 0.22
Smoking duration
 ≤ 8 years 3,050 39 0.71 (0.50–0.99) 0.76 (0.54–1.07)
 8 < duration ≤ 18 2,750 60 1.20 (0.90–1.60) 1.21 (0.90–1.61)
 18 < duration 3,172 93 1.59 (1.24–2.02) 1.34 (1.04–1.73)
P for trend = < 0.01 0.02
Total pack-years
 ≤ 2.3 pack-years 2,800 43 0.84 (0.61–1.17) 0.89 (0.64–1.24)
 2.3< pack-years ≤ 9.8 2,680 51 1.05 (0.77–1.42) 1.01 (0.74–1.38)
 > 9.8 pack-years 2,720 76 1.53 (1.18–1.98) 1.33 (1.02–1.75)
P for trend = 0.01 0.08
Duration of smoking before the first birth among parous women
 Never smoker 7,905 168 Reference Reference
 Initiation after first birth 952 27 1.33 (0.88–1.99) 1.29 (0.85–1.96)
 ≤ 5 years 2,606 48 0.86 (0.63–1.19) 0.86 (0.62–1.19)
 > 5 years 2,858 69 1.14 (0.86–1.50) 1.12 (0.84–1.50)
P for trend = 0.69 0.77
*
adjusted for age, country, BRCA mutation, pregnancy history, contraceptive drug use, alcohol drinking and obesity using time-dependent Cox 
regression model
Int J Cancer. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ko et al. Page 17
Table 4
Association between smoking and risk of ovarian cancer among BRCA mutation carriers
Person-years (Total 15,720) Incident cases (N = 100) Crude HR (95% CI) Adjusted HR* (95% CI)
Smoking history
 Never 9,260 49 Reference Reference
 Ever 6,460 51 1.48 (1.00–2.19) 1.45 (0.96–2.19)
Current smoking history
 Past smoker 3,036 30 1.84 (1.16–2.90) 1.69 (1.06–2.71)
 Current smoker 3,375 21 1.17 (0.70–1.96) 1.25 (0.73–2.12)
P for trend = 0.25 0.22
Age at first smoking
> 19 years 2,531 30 2.22 (1.41–3.50) 1.69 (1.05–2.72)
≤ 19 years 3,627 19 0.98 (0.58–1.66) 1.18 (0.68–2.05)
P for trend = 0.52 0.28
Average packs smoked/week
≤ 3 packs 3,417 27 1.48 (0.93–2.37) 1.72 (1.05–2.81)
3 packs < 2,700 19 1.30 (0.76–2.20) 1.17 (0.68–2.01)
P for trend = 0.20 0.33
Smoking duration
≤ 10 years 3,205 15 0.88 (0.50–1.58) 1.22 (0.67–2.22)
10 years < 3,154 36 2.12 (1.38–3.27) 1.63 (1.04–2.54)
P for trend = < 0.01 0.03
Total pack-years
≤ 4.3 pack-years 3,187 14 0.83 (0.46–1.50) 1.11 (0.60–2.04)
4.3 pack-years < 2,871 32 2.06 (1.32–3.22) 1.68 (1.06–2.67)
P for trend = 0.01 0.03
*
adjusted for age, country, BRCA mutation, pregnancy history, contraceptive drug use, and alcohol drinking using time-dependent Cox regression 
model
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